Prostate cancer treatment may trigger dementia in men
A common hormone therapy to treat prostate cancer may double a man’s risk of dementia, regardless of his age, found a recent study conducted by Penn Medicine researchers. Last year, the researchers discovered a dramatic association between Alzheimer’s disease and androgen deprivation therapy (ADT), a mainstay of treatment for prostate cancer since the 1940s currently used in over a half million men in the United States. This new study suggests a broader neurocognitive risk associated with the testosterone-lowering therapy. While the findings do not prove that ADT increases the risk…
Read More